IL156122A0 - Geldanamycin derivative and method of treating cancer using same - Google Patents

Geldanamycin derivative and method of treating cancer using same

Info

Publication number
IL156122A0
IL156122A0 IL15612202A IL15612202A IL156122A0 IL 156122 A0 IL156122 A0 IL 156122A0 IL 15612202 A IL15612202 A IL 15612202A IL 15612202 A IL15612202 A IL 15612202A IL 156122 A0 IL156122 A0 IL 156122A0
Authority
IL
Israel
Prior art keywords
geldanamycin derivative
same
treating cancer
host
vivo activity
Prior art date
Application number
IL15612202A
Other languages
English (en)
Original Assignee
Nasa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nasa filed Critical Nasa
Publication of IL156122A0 publication Critical patent/IL156122A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15612202A 2001-03-30 2002-03-28 Geldanamycin derivative and method of treating cancer using same IL156122A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28007801P 2001-03-30 2001-03-30
PCT/US2002/010097 WO2002079167A1 (en) 2001-03-30 2002-03-28 Geldanamycin derivative and method of treating cancer using same

Publications (1)

Publication Number Publication Date
IL156122A0 true IL156122A0 (en) 2003-12-23

Family

ID=23071560

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15612202A IL156122A0 (en) 2001-03-30 2002-03-28 Geldanamycin derivative and method of treating cancer using same
IL156122A IL156122A (en) 2001-03-30 2003-05-26 Gladanamycin derivative and compounds containing the cancer treatment derivative

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156122A IL156122A (en) 2001-03-30 2003-05-26 Gladanamycin derivative and compounds containing the cancer treatment derivative

Country Status (19)

Country Link
US (1) US6890917B2 (xx)
EP (1) EP1373215B1 (xx)
JP (1) JP4213472B2 (xx)
KR (1) KR100831133B1 (xx)
CN (1) CN1262542C (xx)
AT (1) ATE334119T1 (xx)
AU (1) AU2002307020B2 (xx)
CA (1) CA2430692C (xx)
CY (1) CY1107484T1 (xx)
DE (1) DE60213386T2 (xx)
DK (1) DK1373215T3 (xx)
ES (1) ES2268068T3 (xx)
IL (2) IL156122A0 (xx)
MX (1) MXPA03007856A (xx)
NZ (1) NZ526133A (xx)
PT (1) PT1373215E (xx)
SI (1) SI21369A (xx)
WO (1) WO2002079167A1 (xx)
ZA (1) ZA200304178B (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
WO2005009345A2 (en) 2003-06-13 2005-02-03 Kosan Biosciences, Inc. 2-desmethyl ansamycin compounds
CA2545457A1 (en) 2003-11-12 2005-06-23 Kosan Biosciences, Inc. 11-o-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
AU2004309395C1 (en) 2003-12-23 2012-10-04 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US7259156B2 (en) 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
US7608611B2 (en) * 2005-03-11 2009-10-27 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
AU2006242446A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
EP1906950A4 (en) * 2005-06-21 2008-09-24 Infinity Discovery Inc ANSAMYCIN FORMULATIONS AND METHODS OF USE
WO2007059116A2 (en) * 2005-11-14 2007-05-24 Abraxis Bioscience, Inc. Geldanamycin derivatives and pharmaceutical compositions thereof
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
US20070207992A1 (en) * 2006-02-21 2007-09-06 Board Of Trustees Of Michigan State University Geldanamycin derivatives and method of use thereof
CN100519536C (zh) * 2006-03-21 2009-07-29 中国医学科学院医药生物技术研究所 一组连有核苷碱基的格尔德霉素衍生物
WO2007130403A2 (en) * 2006-05-02 2007-11-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education REGULATION OF ApoB BY Hspl 10 PROTEINS AND RELATED COMPOSITIONS AND METHODS
KR100796637B1 (ko) * 2006-09-29 2008-01-22 한국생명공학연구원 젤다나마이신 유도체, 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 및치료제
CN100500668C (zh) * 2006-12-19 2009-06-17 中国人民解放军军事医学科学院毒物药物研究所 格尔德霉素衍生物及其制备方法和制备药物的用途
EP2121957A4 (en) * 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
WO2008118601A2 (en) * 2007-02-27 2008-10-02 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Radiolabeled affibody molecules
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
CA2684211A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
WO2009026548A1 (en) 2007-08-23 2009-02-26 The Regents Of The University Of Colorado Hsp90 inhibitors with modified toxicity
JP2011501731A (ja) 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
US20090186039A1 (en) * 2008-01-18 2009-07-23 Jang Sung-Key Novel use of grp 94 in virus infection
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
JP5583680B2 (ja) 2008-10-15 2014-09-03 インフィニティー ファーマスーティカルズ インコーポレイテッド アンサマイシンヒドロキノン組成物
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
EP2471918A4 (en) 2009-09-29 2013-06-05 Takeda Pharmaceutical SCREENING PROCESS
CN102030764B (zh) * 2010-11-12 2012-07-04 中国医学科学院医药生物技术研究所 4，5双氢噻嗪酮格尔德霉素及其制备方法
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
CN102603635B (zh) * 2011-01-21 2016-08-03 杭州华东医药集团生物工程研究所有限公司 格尔德霉素衍生物及其制备方法和用途
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
US9603829B2 (en) 2011-11-14 2017-03-28 The Regents Of The University Of Colorado, A Body Corporate HSP90 inhibitors with modified toxicity
CN102552150B (zh) * 2012-03-02 2013-10-30 首都医科大学 一种格尔德霉素脂质体的制备及应用
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111470A (en) 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Geldanamycin derivative, its preparation, antitumor drug comprising it as active ingredient
JPS55111469A (en) 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS55111419A (en) 1979-02-20 1980-08-28 Kaken Pharmaceut Co Ltd Antitumorigenic agent
CA2166320A1 (en) * 1993-06-29 1995-01-12 Randall James Gallaschun Ansamycin derivatives as antioncogene and anticancer agents
DE69427588T2 (de) * 1993-09-14 2002-04-25 Merck & Co., Inc. HUMANE PROTEIN-TYROSINPHOSPHATASE DECODIERENDE cDNA
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
CA2218523A1 (en) * 1995-05-02 1996-11-07 William J. Welch Inducement of thermotolerance with benzoquinonoid ansamycins
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5948814A (en) * 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
US5952175A (en) * 1997-10-09 1999-09-14 Incyte Pharmaceuticals, Inc. DNA encoding a human progesterone receptor complex p23-like protein
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration

Also Published As

Publication number Publication date
DK1373215T3 (da) 2006-11-13
CA2430692A1 (en) 2002-10-10
CA2430692C (en) 2011-05-31
CY1107484T1 (el) 2013-03-13
WO2002079167A1 (en) 2002-10-10
MXPA03007856A (es) 2003-12-04
SI21369A (sl) 2004-06-30
JP4213472B2 (ja) 2009-01-21
DE60213386T2 (de) 2006-11-23
ES2268068T3 (es) 2007-03-16
CN1262542C (zh) 2006-07-05
EP1373215A1 (en) 2004-01-02
KR100831133B1 (ko) 2008-05-20
CN1484639A (zh) 2004-03-24
IL156122A (en) 2010-11-30
EP1373215B1 (en) 2006-07-26
NZ526133A (en) 2005-08-26
PT1373215E (pt) 2006-12-29
JP2004519514A (ja) 2004-07-02
US6890917B2 (en) 2005-05-10
US20040053909A1 (en) 2004-03-18
ATE334119T1 (de) 2006-08-15
DE60213386D1 (de) 2006-09-07
AU2002307020B2 (en) 2007-06-28
KR20040023581A (ko) 2004-03-18
ZA200304178B (en) 2004-02-17

Similar Documents

Publication Publication Date Title
IL156122A0 (en) Geldanamycin derivative and method of treating cancer using same
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
AU2003253877A1 (en) Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs
WO2005048942A3 (en) Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
WO2005000213A8 (en) Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
WO2005000212A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
AU2838101A (en) Use of melatonin for treating androgenetic and diffuse alopecia
HK1069327A1 (en) Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
GB0020504D0 (en) Therapeutic method
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
PL338140A1 (en) Method of treating diebetes by means of derivatives of thiazolydinone, of insulin secretion stimulating agent and of alpha-glucosidase inhibitor
MXPA03000033A (es) Procedimiento de tratamiento de enfermedades vasculares perifericas, neuropatias perifericas y neuropatias autonomicas.
WO2001034632A3 (en) Aliphatic hydroxy substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents
AU5434899A (en) Cancer treatment
WO2005102367A3 (en) Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
MY118982A (en) Method of reducing tissue damage associated with ischemia
UA32146A (uk) Спосіб оцінки ефективності лікування пародонтита
UA34333A (uk) Спосіб лікування тяжких форм флюорозу зубів
UA36251A (uk) Спосіб комплексної терапії простої шизофренії
WO2004035030A3 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
UA33531A (uk) Спосіб терапії шизофренії